Luke Miller, Yaniv Maddahi, Matthew Shelly, Sudip Nanda, Mohammad Ishaq Arastu
{"title":"First Reported Case of Hemoglobin Graz in the United States: Implications for Misleading Hemoglobin A<sub>1c</sub> Results.","authors":"Luke Miller, Yaniv Maddahi, Matthew Shelly, Sudip Nanda, Mohammad Ishaq Arastu","doi":"10.1210/jcemcr/luae242","DOIUrl":null,"url":null,"abstract":"<p><p>Routine serum studies in a female patient with sustained prediabetic glycated hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) levels, controlled on metformin, yielded an unexpected finding: an elevated HbA<sub>1c</sub> value of ≥14.9% (≥139 mmol/mol) (normal reference range, <5.7% to <39 mmol/mol). Estimated average glucose (EAG) (normal reference range, <126 mg/dL to <7 mmol/L) is a linearly corresponding blood glucose value calculated from HbA<sub>1c</sub> measurements that reflects the average glycemic status over the preceding 3 months. Caution must be used when the EAG provided by the HbA<sub>1c</sub> does not align with blood glucose values obtained around the same period. Our patient carries a rare heterozygous pathogenic variant affecting the β subunit called hemoglobin Graz (Hb Graz), characterized by a histidine for leucine substitution, resulting in clinically silent Hb abnormalities. Individuals without diabetes carrying the Hb Graz pathogenic variant exhibit significantly higher HbA<sub>1c</sub> values when analyzed by high-performance liquid chromatography. Alternative methods of quantifying glycemic control are suggested if the possibility of a confounding variable exists, such as when a HbA<sub>1c</sub>-blood glucose mismatch occurs or unexplainable HbA<sub>1c</sub> levels are detected.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"3 1","pages":"luae242"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCEM case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jcemcr/luae242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Routine serum studies in a female patient with sustained prediabetic glycated hemoglobin A1c (HbA1c) levels, controlled on metformin, yielded an unexpected finding: an elevated HbA1c value of ≥14.9% (≥139 mmol/mol) (normal reference range, <5.7% to <39 mmol/mol). Estimated average glucose (EAG) (normal reference range, <126 mg/dL to <7 mmol/L) is a linearly corresponding blood glucose value calculated from HbA1c measurements that reflects the average glycemic status over the preceding 3 months. Caution must be used when the EAG provided by the HbA1c does not align with blood glucose values obtained around the same period. Our patient carries a rare heterozygous pathogenic variant affecting the β subunit called hemoglobin Graz (Hb Graz), characterized by a histidine for leucine substitution, resulting in clinically silent Hb abnormalities. Individuals without diabetes carrying the Hb Graz pathogenic variant exhibit significantly higher HbA1c values when analyzed by high-performance liquid chromatography. Alternative methods of quantifying glycemic control are suggested if the possibility of a confounding variable exists, such as when a HbA1c-blood glucose mismatch occurs or unexplainable HbA1c levels are detected.